High Bleeding Risk clinical trials

Short radiation, immunotherapy, and chemo for advanced rectal cancer

This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.

Surgery with or without apalutamide for high-risk prostate cancer that has spread a little

This trial tests whether adding the drug apalutamide before and after surgery helps men with high-risk prostate cancer that has spread to a few spots (seen on a special PET scan). You would also receive standard hormone therapy.

Lenvatinib after liver cancer surgery to prevent recurrence

This trial tests whether taking lenvatinib after liver cancer surgery can lower the chance of the cancer coming back. It is for people who have a high risk of recurrence and have recently had their liver tumor completely removed.

Bleeding and clot risk after heart valve procedure

This study looks at patients who had a TAVR procedure (a new valve put in the heart) to understand their risk of bleeding or clots over the next year. It tracks changes in blood thinner medications at 1 month, 90 days, and 1 year to help doctors personalize care.

Donafenib and capecitabine after surgery for biliary cancer with high risk of return

This trial tests whether taking donafenib and capecitabine pills after surgery can help prevent biliary cancer from coming back in people who have a high risk of recurrence. It is for patients whose cancer was completely removed but had certain features that make recurrence more likely.

Blood test to predict risk after surgery for high-risk GIST

This study uses a “liquid biopsy” blood test to look for leftover cancer signals after surgery. It aims to predict how well treatment will work and how likely the cancer is to come back in people with high-risk GIST.

Preventing bleeding from enlarged veins in the esophagus

This study tests whether tying off high-risk veins in the esophagus before starting a common liver cancer treatment can prevent bleeding. It is for people with liver cancer that has spread but who have never had cancer treatment before.

Comparing two doses of albumin for cirrhosis patients with SBP

This trial tests whether a lower dose of albumin works as well as the standard dose for people with cirrhosis and a type of infection called spontaneous bacterial peritonitis (SBP). It aims to see if the low dose can protect kidney function while reducing side effects and costs.

High-flow oxygen during sedation for sleep apnea patients having endoscopy

This study tests if high-flow nasal oxygen can prevent oxygen drops during sedated endoscopy in patients with severe obstructive sleep apnea. It may help people who are at higher risk of breathing problems during the procedure.

Comparison of High- Versus Low-Dose Aspirin for Pregnancy Outcomes in Women at High Risk of Preeclampsia

Testing a new drug for men with BRCA-related prostate cancer

This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.

Study of a new pill for high-risk myelofibrosis

This trial is testing a new pill for people with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It aims to see if the drug can help manage the disease and offer a new treatment option for those who may have limited choices.

Testing Flonoltinib for myelofibrosis after JAK inhibitor failure

This trial tests a new tablet, Flonoltinib, for people with medium-to-high risk myelofibrosis whose prior JAK inhibitor treatment stopped working, caused side effects, or wasn't tolerated. The goal is to see if this new drug can help reduce spleen size and improve symptoms.

Early treatment check for high-risk CLL/SLL

This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.

Cemiplimab before and after surgery for high-risk skin cancer

This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.

Perioperative treatment for high-risk liver cancer using HAIC, donafenib, and sintilimab

This trial tests a combination of treatments—chemotherapy delivered through the liver artery (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—given before and after surgery for liver cancer that has a high chance of coming back. The goal is to see if this approach can lower the risk of recurrence.

Lu-PSMA before prostate surgery for high-risk cancer

This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.

Radiation after kidney-sparing surgery for high-risk ureteral cancer

This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.

Antibody-drug combo with radiation for HER2+ UTUC after surgery

This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.

Clot removal vs clot-busting drugs for severe lung clots

This study compares two ways to treat a large blood clot in the lungs that is causing life-threatening symptoms. One method uses a device to remove the clot, the other uses medicine to dissolve it.

Toripalimab after surgery for high-risk early lung cancer

This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.

Trial of a drug combo for HER2-positive ovarian cancer

This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.

Surgery aftercare for non-clear kidney cancer at high risk

This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.

Capivasertib plus fulvestrant for high-risk lobular breast cancer

This trial tests adding capivasertib to fulvestrant for women with a certain type of breast cancer (invasive lobular carcinoma) that is hormone-receptor positive and has a high risk of coming back. The treatment is given before surgery to see if it works better than fulvestrant alone.